Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Wirden

Showing results (41-50 of 98) with videos related to

Pageof 10
Sort By:
Antimicrobial Agents and Chemotherapy|November 28, 2007
Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavirSidonie Lambert-Niclot, Philippe Flandre, Ana Canestri, et al.
Antimicrobial Agents and Chemotherapy|June 28, 2006
Risk factors for selection of the L74I reverse transcriptase mutation in human immunodeficiency virus type 1-infected patientsMarc Wirden, Bénédicte Roquebert, Anne Derache, et al.
Journal of Medical Virology|May 20, 2005
Resistance mutations before and after tenofovir regimen failure in HIV-1 infected patientsMarc Wirden, Anne Genevieve Marcelin, Anne Simon, et al.
The Journal of Antimicrobial Chemotherapy|March 12, 2011
Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemiaMarc Wirden, Cathia Soulie, Marc-Antoine Valantin, et al.
The Journal of Antimicrobial Chemotherapy|September 8, 2012
Pitfalls of HIV genotypic tropism testing after treatment interruptionMarc Wirden, Cathia Soulié, Slim Fourati, et al.
AIDS (London, England)|June 15, 2012
E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposureSlim Fourati, Isabelle Malet, Sidonie Lambert, et al.
The Journal of Antimicrobial Chemotherapy|May 31, 2022
More HIV-1 RNA detected and quantified with the Cobas 6800 system in patients on antiretroviral therapyMarc Wirden, Romain Palich, Basma Abdi, et al.
Antimicrobial Agents and Chemotherapy|January 27, 2004
Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapyMarc Wirden, Constance Delaugerre, Anne Genevieve Marcelin, et al.
Antimicrobial Agents and Chemotherapy|November 25, 2004
Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patientsAnne-Geneviève Marcelin, Cécile Dalban, Gilles Peytavin, et al.
The Journal of Antimicrobial Chemotherapy|May 28, 2024
The RT M184V resistance mutation clearance in the reservoir is mainly related to CD4 nadir and viral load zenith independently of therapeutic regimen typeElisa Teyssou, Cathia Soulie, Antoine Fauchois, et al.
Pageof 10

Showing results (41-50 of 98) with videos related to

Sort By:
Pageof 10
Antimicrobial Agents and Chemotherapy|November 28, 2007
Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavirSidonie Lambert-Niclot, Philippe Flandre, Ana Canestri, et al.
Antimicrobial Agents and Chemotherapy|June 28, 2006
Risk factors for selection of the L74I reverse transcriptase mutation in human immunodeficiency virus type 1-infected patientsMarc Wirden, Bénédicte Roquebert, Anne Derache, et al.
Journal of Medical Virology|May 20, 2005
Resistance mutations before and after tenofovir regimen failure in HIV-1 infected patientsMarc Wirden, Anne Genevieve Marcelin, Anne Simon, et al.
The Journal of Antimicrobial Chemotherapy|March 12, 2011
Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemiaMarc Wirden, Cathia Soulie, Marc-Antoine Valantin, et al.
The Journal of Antimicrobial Chemotherapy|September 8, 2012
Pitfalls of HIV genotypic tropism testing after treatment interruptionMarc Wirden, Cathia Soulié, Slim Fourati, et al.
AIDS (London, England)|June 15, 2012
E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposureSlim Fourati, Isabelle Malet, Sidonie Lambert, et al.
The Journal of Antimicrobial Chemotherapy|May 31, 2022
More HIV-1 RNA detected and quantified with the Cobas 6800 system in patients on antiretroviral therapyMarc Wirden, Romain Palich, Basma Abdi, et al.
Antimicrobial Agents and Chemotherapy|January 27, 2004
Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapyMarc Wirden, Constance Delaugerre, Anne Genevieve Marcelin, et al.
Antimicrobial Agents and Chemotherapy|November 25, 2004
Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patientsAnne-Geneviève Marcelin, Cécile Dalban, Gilles Peytavin, et al.
The Journal of Antimicrobial Chemotherapy|May 28, 2024
The RT M184V resistance mutation clearance in the reservoir is mainly related to CD4 nadir and viral load zenith independently of therapeutic regimen typeElisa Teyssou, Cathia Soulie, Antoine Fauchois, et al.
Pageof 10